UK now has access to a total of 357 million doses of vaccines from 7 different developers

• UK government has now secured 7 million doses of Moderna vaccine, which will be available in Europe as early as spring 2021
• trials show vaccine is almost 95% effective
• deal means the UK now has access to a total of 357 million doses of vaccines from 7 different developers

The UK government has signed a deal for a further 2 million doses of Moderna’s promising vaccine candidate, bringing the total to 7 million doses for the UK.

Following yesterday’s deal, the UK now has access to enough doses of Moderna’s vaccine candidate for around 3.5 million people.

To be approved for use in the UK, the Moderna vaccine must meet the strict standards of safety and effectiveness of the independent medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA). If it is approved, 7 million doses could start to be delivered to the UK as early as spring 2021 – the same timetable as other countries in Europe.

The latest agreement is part of the government’s strategy to develop a diverse portfolio of promising vaccine candidates. The government has now secured 357 million vaccine doses from 7 different developers, giving the UK the best possible chance of protecting the public from coronavirus as soon as possible.

Business Secretary Alok Sharma said: “It is essential that we continue to bolster our portfolio of vaccine candidates to ensure we’re in the best possible position to protect the public once we see that breakthrough.

“The UK was one of the first countries in Europe to sign a deal with Moderna, and I’m delighted we have been able to secure a further 2 million doses of their promising candidate for the British public.”

On 16 November, Moderna published initial data showing that its candidate is nearly 95% effective in protecting against COVID-19, with no safety issues identified to date. The safety data is still to be released by Moderna to show whether the vaccine is both safe and effective. Moderna is currently conducting phase 3 clinical trials of its vaccine and is using mRNA vaccine technology.

Until all the necessary stages are completed and a vaccine has been approved for use by the medicine regulator, the MHRA, the public must continue to take necessary actions to keep themselves and their loved ones safe, including following the Hands, Face, Space guidance and other public health advice in line with the area they live in.

Health and Social Care Secretary Matt Hancock said: “Every week, we are getting more positive news about the range of vaccines in development, and thanks to the work of our taskforce the UK has pre-ordered hundreds of millions of doses from those companies most advanced in their work.

“This includes buying a further 2 million doses of Moderna’s vaccine, on top of the 5 million we’ve already secured.

“With a wide range of vaccine candidates in our portfolio, we stand ready to deploy a vaccine should they receive approval from our medicines regulator, starting with those who will benefit most.”

Chair of the government’s Vaccine Taskforce Kate Bingham said: “Since its inception in June, one of the most important stated aims of the Vaccines Taskforce has been to secure access to the most promising vaccines across a broad range of technologies – thereby increasing the chances of having a safe and effective prevention as soon as possible against COVID-19.

“Moderna’s vaccine was an important addition to our portfolio and securing an additional 2 million doses further adds to the protection we can provide to the public to end the pandemic.”

Sunday’s deal follows the independent regulator’s confirmation this week that it has received the necessary data of the Pfizer/BioNTech vaccine to progress their review into whether the vaccine meets the required standards. Encouraging results from the phase III trials of the Oxford University/AstraZeneca were also published this week.

The UK’s ability to respond to future pandemics will be strengthened thanks to a new £20 million fund to expand medicines manufacturing, Prime Minister Boris Johnson announced today (Monday 30 November).

The Prime Minister will launch the government’s new capital investment fund, the Medicines and Diagnostic Manufacturing Transformation Fund, while visiting North Wales later today.

This will open up investment opportunities for medicines manufacturers in England, Scotland and Wales – improving our domestic medicine supply chains and creating thousands of highly skilled jobs in the process.

This will put UK companies ahead of global competitors in advanced medicines manufacturing, while helping them respond to future healthcare needs – and increasing the overall health resilience of the UK.

Prime Minister Boris Johnson said: This new £20m fund will significantly increase the capacity and resilience of our medicines and diagnostics manufacturing supply chains and equip us to fight future health crises.

Throughout the pandemic we have seen a coming together of British scientific industry and innovation and this new fund will enhance the UK’s manufacturing capabilities even further.

Business Secretary Alok Sharma said: “The positive and timely response of our medicines manufacturers to the pandemic has been remarkable, but we want to ensure that the UK’s supply chains are even more resilient in the future.

There are huge opportunities for innovation in medicines and diagnostics, and this new fund will put the UK head and shoulders above others, boosting the UK’s capabilities and generating significant economic opportunities across the country.

The pandemic has shown the importance of having a strong domestic medicines and diagnostics manufacturing industry. This new fund has been established to grow and strengthen the UK’s capabilities, by encouraging companies to develop new technologies, build new factories and harness new advances, including bioprocessing, data and using greener manufacturing processes.

With two-thirds of life science manufacturing jobs already outside London and the South East, the fund will also open up economic opportunities in different parts of the UK, creating thousands of new, highly skilled manufacturing jobs while safeguarding existing jobs.

This fund will have an initial pot of £20 million, which will be available from next year, as part of the government’s 2021/2022 Spending Review announced by the Chancellor on 25 November.

Eligible manufacturing companies can bid for the fund to help with their capital costs.

More information will be made available over the coming months, ahead of the fund launching mid-next year. The fund will be run through a competitive process overseen by the Department for Business, Energy and Industrial Strategy.